中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.022 seconds)

    MULTI-DIMENSIONAL OBJECTS
    1.
    发明申请
    MULTI-DIMENSIONAL OBJECTS 审中-公开
    多维对象

    公开(公告)号：US20120102453A1

    公开(公告)日：2012-04-26

    申请号：US12908888

    申请日：2010-10-21

    Applicant: Raymond Patch ,  Rajeev Chauhan

    Inventor： Raymond Patch ,  Rajeev Chauhan

    IPC: G06F9/44 ,  G06F17/30

    CPC classification number: G06F8/24 ,  G06F9/4488

    Abstract: Architecture that enables a software object to be a multi-dimensional object by associating additional dimensions to the object. The object, in addition to the actual data dimension, is now provided with inherent object dimensions that include, but are not limited to, a localization dimension, security dimension, version dimension, personalization dimension, and attributes dimension, for example. The actual data dimension and one or more inherent object dimensions can be added, changed, or modified in realtime. A mapping component maps object relationships between an in-memory form and a tabular form storable in a database. An application programming interface facilitates interaction with the object, and the actual data dimension, and the one or more inherent object dimensions.

    Abstract translation: 通过将附加维度与对象相关联来使软件对象成为多维对象的体系结构。 除了实际数据维度之外，该对象现在具有固有的对象维度，例如包括但不限于定位维度，安全维度，版本维度，个性化维度和属性维度。 实际数据维度和一个或多个固有对象维度可以实时添加，更改或修改。 映射组件映射内存中的形式与数据库中可存储的表格之间的对象关系。 应用程序编程界面便于与对象，实际数据维度以及一个或多个固有对象维度进行交互。

    Personalized Object Dimension
    2.
    发明申请
    Personalized Object Dimension 审中-公开
    个性化对象维度

    公开(公告)号：US20120096048A1

    公开(公告)日：2012-04-19

    申请号：US12907045

    申请日：2010-10-19

    Applicant: Raymond Patch ,  Rajeev Chauhan

    Inventor： Raymond Patch ,  Rajeev Chauhan

    IPC: G06F17/30

    CPC classification number: G06F16/9535

    Abstract: Architecture that associates personalized information (e.g., user preferences) to an object that needs to be displayed in a custom way. The preferences are associated with the object as an inherent object dimension, in addition to the actual data (another dimension). The intrinsic actual data contained within the object itself is considered the first dimension, and additional data and/or metadata make up additional dimensions. Whenever the object is retrieved, the associated personal preferences as the inherent object dimension are returned with the object. The web developer simple uses the associated preferences to build the webpage. If no preferences were defined, the object can be configured to return with a default set of preferences.

    Abstract translation: 将个性化信息（例如，用户偏好）关联到需要以自定义方式显示的对象的架构。 除了实际数据（另一个维度）之外，偏好与对象相关联，作为固有对象维度。 包含在对象本身内部的固有实际数据被认为是第一维，附加数据和/或元数据构成额外的维度。 无论何时检索对象，将返回与对象相关联的个人偏好作为固有对象维度。 Web开发人员简单使用相关的首选项来构建网页。 如果未定义任何首选项，则可以将对象配置为使用默认的首选项返回。

    Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators
    5.
    发明授权
    Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators 有权
    取代苯氧基噻唑烷二酮类作为雌激素相关受体α调节剂

    公开(公告)号：US07846953B2

    公开(公告)日：2010-12-07

    申请号：US12043269

    申请日：2008-03-06

    Applicant: Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

    Inventor： Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

    IPC: A61K31/426 ,  C07D277/04

    CPC classification number: C07D277/34 ,  C07D263/44

    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

    Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖症，升高的血糖水平和胰岛素抵抗。

    Inhibitors of C-FMS kinase
    6.
    发明申请
    Inhibitors of C-FMS kinase 审中-公开

    公开(公告)号：US20050113566A1

    公开(公告)日：2005-05-26

    申请号：US10970903

    申请日：2004-10-22

    Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

    Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

    IPC: A61K31/16 ,  A61K31/195 ,  A61K31/452 ,  A61K31/4545 ,  C07D223/12 ,  C07D265/30 ,  C07D279/12 ,  C07D307/68 ,  C07D405/12 ,  C07D409/12

    CPC classification number: C07D405/12 ,  C07D307/68 ,  C07D409/12

    Abstract: The invention relates to compounds of Formula I: wherein A is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORA, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; or a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; R1 is —H, aryl, —CORa, —CORa, —COORa, —CONRaRb, —SO2Ra or —SO2NRaRb; X is —CO—, —C(═NH)—, —CS—, —CON(Ra)—, —CS(NRa)—, —SO2— or —CRaRb—; Y is —S—, —SO—, —SO2—, —O— or direct link; R2 is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which may be optionally substituted with one or more halogens; and W is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C1-4 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, —CF3, alkoxy, aryloxy, arylalkoxy, —OCF3, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —NHCORaRb, —NHSO2Ra, —NO2, —SORa, —SO3Ra or —SO2NRaRb; or a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —OCO-alkylamino, —OCO-alkylamido, CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

    Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators
    7.
    发明授权
    Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators 有权
    取代苯氧基噻唑烷二酮作为雌激素相关受体α调节剂

    公开(公告)号：US08344009B2

    公开(公告)日：2013-01-01

    申请号：US12899812

    申请日：2010-10-07

    Applicant: Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

    Inventor： Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

    IPC: A61K31/426 ,  C07D277/04

    CPC classification number: C07D277/34 ,  C07D263/44

    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

    Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖，升高的血糖水平和胰岛素抵抗。

    System and method for validating hierarchically-organized messages
    9.
    发明申请
    System and method for validating hierarchically-organized messages 有权
    用于验证分层组织的消息的系统和方法

    公开(公告)号：US20050044093A1

    公开(公告)日：2005-02-24

    申请号：US10643031

    申请日：2003-08-18

    Applicant: Raymond Patch ,  Mathrubootham Janakiraman

    Inventor： Raymond Patch ,  Mathrubootham Janakiraman

    IPC: G06F9/45 ,  G06F17/00 ,  G06F17/21 ,  G06F17/22 ,  G06F17/27 ,  G06F17/30

    CPC classification number: G06F17/2725 ,  G06F17/2247

    Abstract: A mechanism for validating a message, such as an XML message or other hierarchically-organized content. A validation engine walks through the tree represented by the message preferably in depth-first traversal order. Upon encountering each node in the tree, the validation engine consults a validation table to identify a delegate that is to be invoked. The validation engine then invokes the delegate identified for that node, and calls itself recursively on the subtrees of the current node. After the subtrees have been processed, the validation engine again consults the validation table to identify a post-handler for the current node, and then invokes the post-handler. An entry in the validation table may be flagged as “exclusive” to prevent traversal of subtrees of the node corresponding to that entry. Additionally, there may be both global and local validation tables, where the global table is used when a node has no entry in the local table.

    Abstract translation: 用于验证消息的机制，例如XML消息或其他分层组织的内容。 验证引擎优选地以深度优先遍历顺序遍历由消息表示的树。 遇到树中的每个节点时，验证引擎将查询验证表，以标识要调用的代理。 然后，验证引擎调用为该节点标识的委托，并在当前节点的子树上递归调用自身。 处理子树后，验证引擎再次查阅验证表，以识别当前节点的后处理程序，然后调用后处理程序。 验证表中的条目可以标记为“排他”，以防止与该条目相对应的节点的遍历遍历。 另外，可能有全局和局部验证表，其中当节点在本地表中没有条目时使用全局表。

    Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators
    10.
    发明授权
    Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators 有权
    取代的噻唑烷二酮吲唑，吲哚和苯并三唑作为雌激素相关受体α调节剂

    公开(公告)号：US08796256B2

    公开(公告)日：2014-08-05

    申请号：US13114084

    申请日：2011-05-24

    Applicant: Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

    Inventor： Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

    IPC: C07D417/06

    CPC classification number: C07D417/06

    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

    Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖，升高的血糖水平和胰岛素抵抗。

Patent Agency Ranking